What Is KPV? Definition and What Research Reports

Plain definition

KPV is the name given to a very short peptide built from three amino acids in sequence: lysine (single-letter code K), proline (P) and valine (V). The three letters are simply the amino acids written in order, so "KPV" is a spelling of the molecule rather than a brand or an abbreviation of a longer phrase. The same three residues sit at the tail end of a larger, naturally occurring human peptide called alpha-melanocyte-stimulating hormone (alpha-MSH), which is why KPV is usually described in papers as an alpha-MSH-derived or C-terminal fragment. In the published literature KPV appears mainly as a laboratory tool used to ask whether the anti-inflammatory and antimicrobial properties attributed to the full alpha-MSH molecule can be reproduced by its smallest active piece.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes how a compound should be obtained or used.

KPV in biochemical terms

KPV is a linear tripeptide, Lys-Pro-Val, with a molecular weight in the low hundreds of daltons — very small by peptide standards, where many research peptides run to 30 or more residues. Because it is so short, it does not fold into a stable three-dimensional shape the way larger peptides do, and chemists frequently study modified versions instead: acetylated or amidated termini, cysteine-extended analogues, and the covalent dimer [Ac-CKPV]₂, whose solution conformation was characterised by NMR and modelling in a 2005 structural paper (PMID 15946192).

A second biochemical property that recurs across the literature is transport. Di- and tripeptides can be carried across intestinal epithelium by the peptide transporter PepT1, and several groups have used tripeptide motifs as PepT1-directed targeting elements in drug-delivery constructs — for example a PepT1-mediated nanosystem built to carry cyclosporine A to inflamed colon tissue (PMID 31408067) and a later co-assembled nanodrug combining an anti-inflammatory peptide with an immunosuppressant in DSS-induced colitis models (PMID 39211778). In regulatory terms, KPV is not an approved drug product in the United States; material sold for laboratory work is typically labelled research-use-only, and RUO labelling means a substance has not been evaluated as a medicine for people.

Where the sequence comes from

Alpha-MSH is a 13-residue melanocortin peptide long studied for effects reaching beyond pigmentation. Reviews of alpha-MSH described it as a neuroimmunomodulatory molecule with anti-inflammatory activity in multiple experimental systems (PMID 11268347), and a 2007 review in the rheumatology literature grouped alpha-MSH and its fragments together as a proposed class of anti-inflammatory and immunomodulating agents (PMID 17934097). Earlier work reported antimicrobial effects for alpha-MSH peptides, including the C-terminal tripeptide region, against test organisms in vitro (PMID 10670585). KPV therefore entered the literature as a fragment question: how much of the parent molecule's reported activity survives when only three residues remain.

How the term is used in peptide research

Across published work, "KPV" is used in a few consistent ways:

• As a named sequence. Papers write KPV or Lys-Pro-Val interchangeably when describing the tripeptide itself, as in a 2025 study of cultured keratinocytes exposed to fine particulate matter (PMID 40073467).
• As a fragment of alpha-MSH. Reviews of melanocortin biology refer to the C-terminal tripeptide when discussing structure–activity relationships (PMID 17934097).
• As a cargo or ligand in formulation science. Materials papers describe hydrogels and nanocarriers designed to bind, retain or release the peptide at a target tissue, such as a KPV-binding double-network hydrogel studied in inflamed colon (PMID 35245681).
• As shorthand for a research theme. Authors sometimes use the term loosely to signal the broader alpha-MSH anti-inflammatory literature rather than one specific molecule.

Where the term is misused

Several confusions appear in non-academic writing. First, KPV is not alpha-MSH: the parent hormone has additional receptor-binding residues, and findings about one are not automatically findings about the other. Second, KPV is not [Ac-CKPV]₂, which is a chemically distinct dimeric compound with its own characterised structure (PMID 15946192). Third, describing KPV as a proven treatment overstates a literature that is overwhelmingly in vitro and in animal models. Fourth, discussion boards sometimes group KPV with unrelated research peptides as though they shared a mechanism; a 2026 critical review of peptide and peptide-analog use in sport and bodybuilding noted how quickly such products move ahead of the evidence supporting them (PMID 41880199).

Related terms

What the published literature reports

Antimicrobial and antifungal observations

A 2000 paper in the Journal of Leukocyte Biology reported antimicrobial effects of alpha-MSH peptides in laboratory assays, extending the interest in the molecule beyond immune signalling alone (PMID 10670585). The 2005 structural study of [Ac-CKPV]₂ was framed around a candidacidal peptide derived from alpha-MSH and described its three-dimensional solution structure (PMID 15946192).

Intestinal inflammation models

Materials scientists have used the tripeptide as a payload in colon-directed constructs. Researchers reported that a KPV-binding double-network hydrogel was studied for restoration of the gut mucosal barrier in an inflamed colon model (PMID 35245681). Related colitis work has followed similar logic with other cargoes, including a temperature-sensitive hydrogel acting as biomimetic mucus in murine ulcerative colitis (PMID 38289234) and the PepT1-targeted co-assembled nanodrug described above (PMID 39211778).

Skin and keratinocyte work

A 2025 study in Tissue & Cell examined Lys-Pro-Val in keratinocytes exposed to fine dust and reported effects on apoptosis and inflammatory signalling linked to oxidative stress and the MAPK/NF-kappaB pathway (PMID 40073467). The study was conducted in cultured cells, not in people.

Delivery chemistry

Because peptides are degraded in the gastrointestinal tract, a large share of the surrounding literature concerns delivery. A 2026 Science Advances report described inflammation-triggered self-immolative conjugates designed to let peptides cross gastrointestinal barriers after oral administration (PMID 41533788). Work of this kind explains why so many KPV papers are authored by materials and pharmaceutics groups rather than clinicians.

Adverse events: What Studies Report

The verified papers summarised here are laboratory and animal studies focused on mechanism, formulation and delivery; they do not constitute a human safety database, and no controlled human tolerability data are described in them. The 2026 critical review of peptide and peptide-analog use in sport and bodybuilding discussed unapproved peptide products circulating outside regulated channels, where composition and purity are not independently assured (PMID 41880199). The 2025 keratinocyte study measured cellular endpoints in culture rather than safety outcomes in people (PMID 40073467), and the colon hydrogel work was carried out in an animal model of inflamed colon (PMID 35245681).

References

• Antimicrobial effects of alpha-MSH peptides (Journal of Leukocyte Biology, 2000)
• The neuroimmunomodulatory peptide alpha-MSH (Annals of the New York Academy of Sciences, 2000)
• Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2 (The Journal of Peptide Research, 2005)
• alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs (Annals of the Rheumatic Diseases, 2007)
• A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis (Biomaterials Science, 2019)
• A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon (Acta Biomaterialia, 2022)
• Growth Factors-Loaded Temperature-Sensitive Hydrogel as Biomimetic Mucus Attenuated Murine Ulcerative Colitis via Repairing the Mucosal Barriers (ACS Applied Materials & Interfaces, 2024)
• PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced colitis (Frontiers in Pharmacology, 2024)
• Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kappaB pathway (Tissue & Cell, 2025)
• Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers (Science Advances, 2026)
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review (The Journal of Sports Medicine and Physical Fitness, 2026)